Julia Minitti is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patent and innovation strategies practice. Julia counsels clients in the biotechnology, chemical, and pharmaceutical industries on a wide range of intellectual property issues, including patent portfolio development and management, Orange Book listing, patentability, non-infringement, and freedom to operate. She also advises clients in connection with various transactions, such as mergers and acquisitions, licenses, and venture financings.
Julia obtained her Ph.D. in organic chemistry from Brown University, where she worked on synthetic methodology for creating heterocycles and catalyzing conjugate additions. Prior to graduate school, she worked as a medicinal chemist at Albany Molecular Research.
Julia Minitti is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patent and innovation strategies practice. Julia counsels clients in the biotechnology, chemical, and pharmaceutical industries on a wide range of intellectual property issues, including patent portfolio development and management, Orange Book listing, patentability, non-infringement, and freedom to operate. She also advises clients in connection with various transactions, such as mergers and acquisitions, licenses, and venture financings.
Julia obtained her Ph.D. in organic chemistry from Brown University, where she worked on synthetic methodology for creating heterocycles and catalyzing conjugate additions. Prior to graduate school, she worked as a medicinal chemist at Albany Molecular Research.
- J.D., Santa Clara University School of Law
- Ph.D., Organic Chemistry, Brown University
- B.S., Chemistry, Union CollegeCum Laude
- Named to the 2025 and 2026 Lawdragon “500 X – The Next Generation” lists
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., Santa Clara University School of Law
- Ph.D., Organic Chemistry, Brown University
- B.S., Chemistry, Union CollegeCum Laude
- Named to the 2025 and 2026 Lawdragon “500 X – The Next Generation” lists
- State Bar of California
- U.S. Patent and Trademark Office
Select Clients
- Aeovian Pharmaceuticals
- Autonomous Medical Devices Inc.
- Centessa Pharmaceuticals Limited
- Day One Biopharmaceuticals, Inc.
- Edgewise Therapeutics
- EpiBiologics, Inc.
- Presage Biosciences
- Quanta Therapeutics, Inc.
- Soley Therapeutics, Inc.
- Terremoto Biosciences, Inc
Select Clients
- Aeovian Pharmaceuticals
- Autonomous Medical Devices Inc.
- Centessa Pharmaceuticals Limited
- Day One Biopharmaceuticals, Inc.
- Edgewise Therapeutics
- EpiBiologics, Inc.
- Presage Biosciences
- Quanta Therapeutics, Inc.
- Soley Therapeutics, Inc.
- Terremoto Biosciences, Inc
Select Publications
- Co-author with W.C. Trenkle, D.A. Sweigart, and S. Son, "Highly Efficient 1,4-Additions of Electron Deficient Aryl Boronic acids with a Novel Rh (I) Catalyst," 25(15) Organometallics 3548-51, 2006
- Co-author with M.D. Faust Jr. and W.C. Trenkle, "Cytosine Analogues from Substituted Acetonitriles via Thorpe Condensation," 5(18) Organic Letters 3333-5, 2003
- Co-author with J.C. Adrian Jr., R.J. Fox, J.E. Chick, A.D. Hunter, and R.A. Nicklow, "Chlorotitanium Enolate Addition to Aldimines: A Stereoselective Route to α-Oxy-β-Substituted β-Amino Esters," 65(19) The Journal of Organic Chemistry 6264-7, 2000
- Co-author with J.C. Adrian Jr. and L. Hassib, "β-Amino Acids via the Addition of Reformatsky Reagents to Imines: Restraining Effects of the o-Methoxyphenyl Substituent," 40 Tetrahedron Letters 2457, 1999
Select Publications
- Co-author with W.C. Trenkle, D.A. Sweigart, and S. Son, "Highly Efficient 1,4-Additions of Electron Deficient Aryl Boronic acids with a Novel Rh (I) Catalyst," 25(15) Organometallics 3548-51, 2006
- Co-author with M.D. Faust Jr. and W.C. Trenkle, "Cytosine Analogues from Substituted Acetonitriles via Thorpe Condensation," 5(18) Organic Letters 3333-5, 2003
- Co-author with J.C. Adrian Jr., R.J. Fox, J.E. Chick, A.D. Hunter, and R.A. Nicklow, "Chlorotitanium Enolate Addition to Aldimines: A Stereoselective Route to α-Oxy-β-Substituted β-Amino Esters," 65(19) The Journal of Organic Chemistry 6264-7, 2000
- Co-author with J.C. Adrian Jr. and L. Hassib, "β-Amino Acids via the Addition of Reformatsky Reagents to Imines: Restraining Effects of the o-Methoxyphenyl Substituent," 40 Tetrahedron Letters 2457, 1999
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
- Privacy Policy
- Terms of Use
- Accessibility